M E Lacouture
Affiliation: Northwestern University
- The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitorsMario E Lacouture
Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
J Support Oncol 4:236-8. 2006
- Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspectiveM E Lacouture
SERIES Clinic, Department of Dermatology and Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Skin Therapy Lett 12:1-5. 2007....
- Clinical management of EGFRI dermatologic toxicities: US perspectiveMario E Lacouture
Department of Dermatology, Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
Oncology (Williston Park) 21:17-21. 2007..Two dermatologists who treat high numbers of patients affected by these EGFRI-induced cutaneous side effects submit their recommendations for management...
- Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinibM E Lacouture
Department of Dermatology, SERIES Clinic, Northwestern University s Feinberg School of Medicine, Chicago, IL 60611, USA
Ann Oncol 19:1955-61. 2008..This study examined clinicopathological findings and management of hand foot skin reaction (HFSR) to sorafenib and sunitinib in a dermatology referral center for cancer-related toxic effects...
- Analysis of dermatologic events in patients with cancer treated with lapatinibM E Lacouture
Department of Dermatology, Northwestern University, 676 North St Claire Street, Suite 1600, Chicago, IL 60611 2941, USA
Breast Cancer Res Treat 114:485-93. 2009..Dermatologic events (DEs) in patients with cancer treated with lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR [ErbB1]) and HER2 (ErbB2), were characterized...
- Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitorM E Lacouture
Section of Dermatology, Department of Medicine, University of Chicago, IL, USA
Clin Exp Dermatol 31:783-5. 2006..This side-effect is of clinical importance, as early recognition is critical for early treatment and may represent a source of additional morbidity to these patients...
- Mechanisms of cutaneous toxicities to EGFR inhibitorsMario E Lacouture
SERIES Clinic and Cancer Skin Care Program, Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Suite 1600, Chicago, Illinois 60611, USA
Nat Rev Cancer 6:803-12. 2006..There is an urgent need for an improved understanding of these toxicities to develop adequate staging systems and mechanistically driven therapies, and to ensure quality of life and consistent antineoplastic therapy...
- Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinibMario E Lacouture
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
Oncologist 13:1001-11. 2008..Based on these proceedings, recommendations for the management of HFSR have been provided to offer patients the best possible quality of life while taking these drugs and to optimize the patient benefit associated with MKI therapy...
- A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertensionM Gomberg-Maitland
Section of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
Clin Pharmacol Ther 87:303-10. 2010..The most common adverse events were moderate skin reactions on the hands and feet and alopecia. Our conclusion was therefore that this is a tolerable dosing regimen for testing the therapeutic activity of sorafenib in PAH patients...
- Higher severity grade of erlotinib-induced rash is associated with lower skin phototypeM Luu
Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Clin Exp Dermatol 36:733-8. 2011..Because the level of the biological pigment melanin correlates with increased protection against UVR, we hypothesized that lighter levels of skin pigmentation are associated with greater severity of rash...
- Quality of life in patients with dermatologic toxicities: Experience from the SERIES clinicJ Gordon
Department of Dermatology, Northwestern University, Chicago, IL Memorial Sloan Kettering Cancer Center, New York, NY Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL Department of Dermatology at Northwestern s Feinberg School of Medicine, Chicago, IL
J Clin Oncol 29:9104. 2011..We systematically investigated their impact on dQoL in patients seen at the SERIES clinic, a referral center for management of dTs stemming from anti-cancer therapies...
- Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinibS E Rosenbaum
Department of Dermatology, Northwestern University, Feinberg School of Medicine, 676 N St Clair St, Suite 1600, Chicago, IL 60611, USA
Support Care Cancer 16:557-66. 2008..However, sunitinib is frequently associated with dermatological adverse reactions. The physical and psychosocial impact of frequent dermatological toxicities can affect consistent antineoplastic therapy and quality of life...
- Economic impact associated with the management of dermatologic adverse drug reactions (dADRs) induced by EGFR inhibitors (EGFRIs) in lung cancerT Abraham
Northwestern University, Chicago, IL
J Clin Oncol 26:19094. 2008....
- Correlation of patient characteristics and NCI-Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor-induced rashJ N Witherspoon
Northwestern University, Chicago, IL
J Clin Oncol 26:9559. 2008..These events lead to decreased quality of life, which lead to dose modification or discontinuation in up to 17% of patients. This study examines factors associated with dermatology-related QoL in patients treated with EGFRIs...
- Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibodyM E Lacouture
Section of Dermatology, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL, USA
Clin Exp Dermatol 30:46-8. 2005..These are two of the few cases in the literature showing that rituximab is an effective and well-tolerated treatment for radiotherapy-relapsing primary cutaneous B cell lymphoma...
- The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysisY Balagula
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 160 East 53rd Street, New York, NY 10022, USA
Ann Oncol 22:2366-74. 2011..We carried out a systematic review and meta-analysis of published studies to quantify the incidence and risk of high-grade acneiform rash with combination therapy...
- Variability in the reporting of dermatologic adverse reactions (dADRs) to EGFR inhibitors cetuximab (C) and panitumumab (P) in the treatment of metastatic colorectal cancer (mCRC)S B Hammerman
Northwestern University, Chicago, IL
J Clin Oncol 26:15045. 2008..Thus, our study examines the variability of EGFRI induced dADR reporting in mCRC clinical trials...
- Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC)M L Maitland
University of Chicago, Chicago, IL Northwestern University, Chicago, IL
J Clin Oncol 26:8089. 2008..Better characterizing EIRR will advance development of biomarkers for individualizing EGFR-inhibitor therapy...
- Management of dermatologic toxicities associated with epidermal growth factor inhibitors (EGFRIs) and multikinase inhibitors (MKIs)D Chen
Department of Dermatology, Northwestern University, Chicago, IL Memorial Sloan Kettering Cancer Center, New York, NY Northwestern University, Chicago, IL Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL
J Clin Oncol 29:e19624. 2011..Current management strategies of these dTs are based largely on anecdotal evidence. We use experience from our SERIES clinic, a referral center for anticancer therapy dTs, to help develop evidence-based treatment recommendations...
- Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: Impact on quality of life (QoL)R H Huggins
Northwestern University, Chicago, IL Pennsylvania State University College of Medicine, Hershey, PA
J Clin Oncol 26:16122. 2008..This study investigated the overall impact of HFSR on QoL and its relationship with clinical severity...
- Life-threatening dermatologic toxicities to cancer drug therapy: An assessment of the published peer-reviewed literatureJ Sorrell
Northwestern University, Chicago, IL University of New Mexico, Albuquerque, NM
J Clin Oncol 27:e20592. 2009..Currently, reporting is in the range of 1-7 cases of SJS and 0.4-1.2 of TEN/million persons/year, with mortality as high as 35%. The association of cancer drug therapy with SJS/TEN has been uncommonly addressed...
- Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysisV R Belum
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Clin Exp Dermatol 41:8-15. 2016..The adverse event (AE) profile is similar to that of other newer angiogenesis inhibitors. Hand-foot skin reaction (HFSR) is an important dose-limiting dermatological adverse event of this class of drugs...
- An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitorsBeth Eaby
University of Pennsylvania, Philadelphia, PA, USA
Clin J Oncol Nurs 12:283-90. 2008..The result was a proposal for a simple, three-tiered grading system for skin toxicities related to HER1/EGFR inhibitors to be used in therapeutic decision making and as a framework for building a stepwise approach to intervention...
- Hand-foot and stump syndrome to sorafenibSusan E Lai
Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
J Clin Oncol 25:341-3. 2007
- Non-rash skin toxicities associated with novel targeted therapiesMario E Lacouture
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL 48201, USA
Clin Lung Cancer 8:S36-42. 2006..This review discusses several non-rash dermatologic toxicities observed with targeted therapeutic agents and guidelines for their diagnosis and treatment...
- Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinibMinnelly Luu
Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
Photodermatol Photoimmunol Photomed 23:42-5. 2007....
- Temporal dependence of the effect of radiation on erlotinib-induced skin rashMario E Lacouture
J Clin Oncol 25:2140; author reply 2141. 2007
- Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical managementThomas J Lynch
Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Oncologist 12:610-21. 2007..The goal is to maximize quality of life in patients who are being treated with these agents--many of whom will be on these drugs for several months or even years...
- Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancerMario E Lacouture
Cancer Skin Care Program and SERIES Clinic, Department of Dermatology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Ill 60611 2941, USA
Cancer Nurs 30:S17-26. 2007..Effective management of these adverse effects may lessen the chance of suboptimal therapy and requires an understanding of the underlying pathophysiology, as well as knowledge of useful strategies for alleviating these effects...
- Dermatologic challenges in cancer patients and survivorsRania Agha
Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Oncology (Williston Park) 21:1462-72; discussion 1473, 1476, 1481 passim. 2007..This review provides a basis for the understanding of dermatologic events in the oncology setting, in order to promote attentive care to cutaneous health in cancer patients and survivors...
- Clinical presentation and pathophysiology of EGFRI dermatologic toxicitiesEdith P Mitchell
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Oncology (Williston Park) 21:4-9. 2007..Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies...
- Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelaeLynne I Wagner
Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Northwestern University, Feinberg Medical School, Chicago, IL 60611, USA
Oncology (Williston Park) 21:34-6. 2007..Cognitive behavioral strategies may also be useful in helping patients manage anxiety and depression associated with any changes in their social function caused by skin rash, as well as distress associated with having a cancer diagnosis...
- Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey resultsSusan L Boone
Department of Dermatology, SERIES Clinic, Northwestern University s Feinberg School of Medicine, Chicago, Ill 60611, USA
Oncology 72:152-9. 2007..The survey results support that attentive cutaneous care is important in patients treated with EGFR inhibitors, and that proactive/combined interventions may enhance quality of life and optimize consistent drug administration...
- Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysisDavid Chu
Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
Acta Oncol 47:176-86. 2008..This study was conducted to determine the risk of developing HFSR among patients receiving sorafenib...
- Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of expertsRoger von Moos
Medical Oncology, Kantonsspital Graubunden, Loestrasse 170, Chur 7000, Switzerland
Eur J Cancer 44:781-90. 2008..It can cause considerable discomfort and lead to therapy interruption. Numerous approaches to HFS management have been reported, but there is no consensus...
- The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignanciesLavanya Kondapalli
Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA
J Am Acad Dermatol 53:291-302. 2005..These drugs will have important implications in clinical dermatology, based on their expected frequent use in the treatment of dermatologic malignancies, and their associated cutaneous side effects...
- Skin rash in a transplant patient receiving multiple drugsMario E Lacouture
Section of Dermatology, University of Chicago Hospitals, USA
Cleve Clin J Med 70:1071-5. 2003